Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960615 | 1.00 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL1960616 | 1.00 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL7142926 | 1.00 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL31193421 | 1.00 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL4551608 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL4551607 | 0.99 | ITGB3 (0.74) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL8194540 | 0.96 | ITGB3 (0.71) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL157968 | 0.96 | ITGB3 (0.74) | ITGB3ITGA2BLMNAPTPN1 | |
| SCHEMBL157969 | 0.96 | ITGB3 (0.74) | ITGB3ITGA2BLMNAPTPN1 | |
| SCHEMBL8530276 | 0.96 | ITGB3 (0.74) | ITGB3ITGA2BLMNAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521594-B1 | Cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding; high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors | LA JOLLA CANCER RESEARCH FOUNDATION | 2003-02-18 | — | — | US | disclosed |
| US-6395873-B1 | CYCLIC PEPTIDE; ANTICOAGULANT | LA JOLLA CANCER RESEARCH FOUNDATION | 2002-05-28 | — | — | US | disclosed |
| EP-0705274-B1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | JOLLA CANCER RES FOUND (US) | 2000-08-30 | — | — | EP | disclosed |
| US-6017877-A | Method and composition for treating thrombosis | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0873357-A2 | ANTITHROMBOTIC AGENTS AND METHODS OF USE | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5780303-A | Method and composition for treating thrombosis | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5672585-A | HYDROPHOBIC AND CATIONIC AMINO ACID-CONTAINING CYCLIC (POLY)PEPTIDES HAVING HIGH AFFINITY FOR GLYCOPROTEIN IIB/IIIA RECEPTORS TO INHIBIT PLATELET AGGREGATION WITHOUT PROLONGED BLEEDING | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1997025343-A2 | ANTITHROMBOTIC AGENTS AND METHODS OF USE | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5612311-A | CYCLIC PEPTIDES | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0705274-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000544-A1 | METHOD AND COMPOSITION FOR TREATING THROMBOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-01-05 | — | — | WO | disclosed |